Publications
"Basic concepts and methods for joint models of longitudinal and survival data." J Clin Oncol 28, no. 16 (2010): 2796-801.
"Bayesian design of noninferiority trials for medical devices using historical data." Biometrics 67, no. 3 (2011): 1163-70.
"Bayesian influence analysis: a geometric approach." Biometrika 98, no. 2 (2011): 307-323.
"Fixed and random effects selection in mixed effects models." Biometrics 67, no. 2 (2011): 495-503.
"Maximum likelihood estimation in generalized linear models with multiple covariates subject to detection limits." Stat Med 30, no. 20 (2011): 2551-61.
"Multiscale Adaptive Regression Models for Neuroimaging Data." J R Stat Soc Series B Stat Methodol 73, no. 4 (2011): 559-578.
"Sample size and power determination in joint modeling of longitudinal and survival data." Stat Med 30, no. 18 (2011): 2295-309.
"Assessing Similarity to Existing Drugs to Decide Whether to Continue Drug Development." Stat Biopharm Res 4, no. 3 (2012): 293-300.
"Bayesian Case Influence Measures for Statistical Models with Missing Data." J Comput Graph Stat 21, no. 1 (2012): 253-271.
"Bayesian influence measures for joint models for longitudinal and survival data." Biometrics 68, no. 3 (2012): 954-64.
"Bayesian lasso for semiparametric structural equation models." Biometrics 68, no. 2 (2012): 567-77.
"Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes." Biometrics 68, no. 2 (2012): 578-86.
"Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690." BMC Med Res Methodol 12 (2012): 183.
"Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study." Biometrika 99, no. 1 (2012): 167-184.
"Intrinsic Regression Models for Medial Representation of Subcortical Structures." J Am Stat Assoc 107, no. 497 (2012): 12-23.
JMDesign: Statistical design for joint models of longitudinal and survival data (R).. v1.1 ed., 2012.
"Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs." Stat Med 31, no. 28 (2012): 3597-616.
"Missing data in clinical studies: issues and methods." J Clin Oncol 30, no. 26 (2012): 3297-303.
"PERTURBATION AND SCALED COOK'S DISTANCE." Ann Stat 40, no. 2 (2012): 785-811.
"Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs." Stat Med 32, no. 23 (2013): 3972-90.
"Bayesian modeling and inference for clinical trials with partial retrieved data following dropout." Stat Med 32, no. 24 (2013): 4180-95.
"Bayesian spatial transformation models with applications in neuroimaging data." Biometrics 69, no. 4 (2013): 1074-83.
"Estimating time-varying effects for overdispersed recurrent events data with treatment switching." Biometrika 100, no. 2 (2013): 339-354.
"Meta-analysis of gene-level associations for rare variants based on single-variant statistics." Am J Hum Genet 93, no. 2 (2013): 236-48.
"Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials." Stat Med 33, no. 27 (2014): 4715-33.
"Bayesian Case-deletion Model Complexity and Information Criterion." Stat Interface 7, no. 4 (2014): 531-542.
"Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome." Biometrics 70, no. 4 (2014): 1003-13.
"Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching." Lifetime Data Anal 20, no. 1 (2014): 76-105.
"Bayesian Generalized Low Rank Regression Models for Neuroimaging Phenotypes and Genetic Markers." J Am Stat Assoc 109, no. 507 (2014): 997-990.
"Bayesian meta-experimental design for evaluating cardiovascular risk." In Quantitative Evaluation if Safety in Drug Development: Design, Analysis and Reporting, 13-38. Boca Raton: Chapman & Hall / CRC Press, 2014.
"Bayesian Sensitivity Analysis of Statistical Models with Missing Data." Stat Sin 24, no. 2 (2014): 871-896.
"Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program." Stat Med 33, no. 9 (2014): 1600-18.
"Bayesian Transformation Models for Multivariate Survival Data." Scand Stat Theory Appl 41, no. 1 (2014): 187-199.
"Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses." J Biopharm Stat 24, no. 4 (2014): 817-33.
"Functional-mixed effects models for candidate genetic mapping in imaging genetic studies." Genet Epidemiol 38, no. 8 (2014): 680-91.
"Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates." Stat Med 33, no. 26 (2014): 4560-76.
Macros for missing data (SAS).., 2014.
"Multivariate recurrent events in the presence of multivariate informative censoring with applications to bleeding and transfusion events in myelodysplastic syndrome." J Biopharm Stat 24, no. 2 (2014): 429-42.
Power calculations and confidence intervals in phase II design with over enrollment (SAS/R).., 2014.
"Sample size determination in shared frailty models for multivariate time-to-event data." J Biopharm Stat 24, no. 4 (2014): 908-23.
"Use of historical control data for assessing treatment effects in clinical trials." Pharm Stat 13, no. 1 (2014): 41-54.
"Assessing temporal agreement between central and local progression-free survival times." Stat Med 34, no. 5 (2015): 844-58.
"Bayesian Inference for Multivariate Meta-regression with a Partially Observed Within-Study Sample Covariance Matrix." J Am Stat Assoc 110, no. 510 (2015): 528-544.
"Bayesian probability of success for clinical trials using historical data." Stat Med 34, no. 2 (2015): 249-64.
"BFLCRM: A BAYESIAN FUNCTIONAL LINEAR COX REGRESSION MODEL FOR PREDICTING TIME TO CONVERSION TO ALZHEIMER'S DISEASE." Ann Appl Stat 9, no. 4 (2015): 2153-2178.
"Comment." Stat Biopharm Res 7, no. 4 (2015): 357-358.
"A counterfactual p-value approach for benefit-risk assessment in clinical trials." J Biopharm Stat 25, no. 3 (2015): 508-24.
"Diagnostic Measures for the Cox Regression Model with Missing Covariates." Biometrika 102, no. 4 (2015): 907-923.
"Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials." J Biopharm Stat 25, no. 6 (2015): 1206-14.
"Hypothesis testing for two-stage designs with over or under enrollment." Stat Med 34, no. 16 (2015): 2417-26.
"Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group." Stat Med 34, no. 14 (2015): 2181-95.
"The power prior: theory and applications." Stat Med 34, no. 28 (2015): 3724-49.
"Quantifying the average of the time-varying hazard ratio via a class of transformations." Lifetime Data Anal 21, no. 2 (2015): 259-79.
"Responses to discussants of 'Joint modeling of survival and longitudinal non-survival data: current methods and issues. report of the DIA Bayesian joint modeling working group'." Stat Med 34, no. 14 (2015): 2202-3.
"SPReM: Sparse Projection Regression Model For High-dimensional Linear Regression." J Am Stat Assoc 110, no. 509 (2015): 289-302.
"The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies." J Biopharm Stat 25, no. 1 (2015): 66-88.
binDesign: Bayesian sample size for non-inferiority randomized trials with binary data (SAS).., 2016.
"JMFit: A SAS Macro for Joint Models of Longitudinal and Survival Data." J Stat Softw 71, no. 3 (2016).
Network Meta-analysis for Ordinal Outcomes: Applications in Comparing Crohn's Disease Treatments., 2016.
"Nine-year change in statistical design, profile, and success rates of Phase II oncology trials." J Biopharm Stat 26, no. 1 (2016): 141-9.
normDesign: Bayesian sample size for non-inferiority randomized trials with normal data (SAS).., 2016.
"Practical designs for Phase I combination studies in oncology." J Biopharm Stat 26, no. 1 (2016): 150-66.
"The rapid enrollment design for Phase I clinical trials." Stat Med 35, no. 15 (2016): 2516-24.
"SAS Macro BSMED: Bayesian survival meta-experimental design using historical data." In Pharmaceutical Statistics Using SAS. Cary: SAS Institute Inc, 2016.
"SR-HARDI: Spatially Regularizing High Angular Resolution Diffusion Imaging." J Comput Graph Stat 25, no. 4 (2016): 1195-1211.
"Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases." J Clin Oncol 34, no. 9 (2016): 945-52.
"Two-stage design for phase II oncology trials with relaxed futility stopping." Stat Interface 9, no. 1 (2016): 93-98.
"Bayesian clinical trial design using Markov models with applications to autoimmune disease." Contemp Clin Trials 63 (2017): 73-83.
"Bayesian longitudinal low-rank regression models for imaging genetic data from longitudinal studies." Neuroimage 149 (2017): 305-322.
"Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data with Applications to Cancer Clinical Trials." J Comput Graph Stat 26, no. 1 (2017): 121-133.
"Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?" J Biopharm Stat 27, no. 3 (2017): 457-476.
"Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat 27, no. 3 (2017): 477-494.
"Pattern mixture models for clinical validation of biomarkers in the presence of missing data." Stat Med 36, no. 19 (2017): 2994-3004.
"Regression Models on Riemannian Symmetric Spaces." J R Stat Soc Series B Stat Methodol 79, no. 2 (2017): 463-482.
"Selection of the initial design for the two-stage continual reassessment method." J Biopharm Stat 27, no. 3 (2017): 495-506.
"Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects." J Biopharm Stat 27, no. 6 (2017): 933-944.
"Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer." Breast Cancer Res Treat 166, no. 1 (2017): 167-177.
"Age and African-American race impact the validity and reliability of the asthma control test in persistent asthmatics." Respir Res 19, no. 1 (2018): 152.